Curriculum
Module 12 · 90 min
Capstone: Cross-Pathway Reasoning
Integrate metabolism, signaling, and cell-fate decisions in a series of clinical and research vignettes.
CoreClinicalResearch
Topics
What this module covers
- 01Case 1: Metformin in PCOS — metabolic and signaling crosstalk
- 02Case 2: Resistance to EGFR inhibitor in NSCLC
- 03Case 3: CAR-T cytokine release
- 04Case 4: Statin myopathy — the mevalonate pathway
Learning objectives
By the end of this module you will be able to
- L01Apply pathway reasoning to four open-ended clinical scenarios.
- L02Defend a treatment plan referencing both efficacy and pathway-level toxicity.
- L03Identify a research question raised by each case.
Expected takeaways
What you should walk away believing
- →Cross-pathway thinking is what separates pattern-matchers from problem-solvers.
- →Every failure of targeted therapy is a clue about pathway architecture.
Core summary
At the Core level
The capstone module is structured as four cases. Each case asks you to reach across earlier modules and reason at pathway level under clinical pressure.
Evidence-graded claims
Claims, scored A–F
C
Statin myopathy involves CoQ10 depletion via mevalonate inhibition
Mechanism plausible; supplementation evidence weak.
Quiz
Check your understanding
Q1. Why does T790M mediate resistance to first-gen EGFR TKIs?
Flashcards
Lock it in
1 / 2
Front
Why does metformin lower glucose?
Click to flip